Liver Inflammation – PharmaLive

AbbVie’s Mavyret Approved for Hep C in Pediatric and Adolescent Patients

Adolescents, Approvals, Children, FDA, FDA/Regulatory, Hepatitis C, Liver Cirrhosis, Liver Inflammation, National Health Service (NHS), New Indications, U.S. Centers for Disease Control and Prevention

The U.S. FDA approved AbbVie’s Mavyret for all six strains of hepatitis C in children ages 12 to 17 years. The drug was approved for adults 18 years or older during 2017.

May 1, 2019/by BioSpace